ascopubs.org

A biomarker trial of BR-DIM (BioResponse 3,3’- Diindolylmethane) in patients with prostate cancer who undergo prostatectomy.

External validation of current nomograms in invasive bladder cancer. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not include a full text component.
ascopubs.org

The effects of BR-DIM (BioResponse 3, 3’-Diindolylmethane) administered pre-prostatectomy on the androgen receptor (AR).

Public perception of cancer risk. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract does not include a full text component.